Skip to content

Research on the role of residual renal function in patients receiving hemodialysis by Chinese medicine called "shenwei compound"

Research on the role of residual renal function in patients receiving hemodialysis by Chinese medicine called "shenwei compound"

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-14005644
Enrollment
Unknown
Registered
2014-10-28
Start date
2014-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure

Interventions

The treatment group:Foundation treatment + traditional Chinese medicine compound renal atrophy
The control group:Foundation treatment

Sponsors

Luzhou Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Ranging in age from 18 to 75 years old, gender not limited; (2) Conform to the standard case diagnosis of chronic renal insufficiency; (3) Maintenance hemodialysis patients; (4) Liver function, electrocardiogram (ecg) is normal, routine blood: WBC more than 4*10^9/L or less than 10*10^9/L and platelet more than 60*10^12/L, hemoglobin more than 60g/L; (5) Voluntary participation and cooperation with physicians, signed a written informed consent.

Exclusion criteria

Exclusion criteria: (1) Older than 75 years of age or younger than 18; (2) Do not accord with standard of chronic renal failure diagnosis; (3) With severe infections and poor control of heart failure, hypertension, diabetes, low blood pressure of patients, mental patients; (4) The liver function and abnormal electrocardiogram (ecg), blood routine: WBC more than 4*10^9/L or more than 10*10^9/L platelet less than 60*10^12/L, hemoglobin less than 60g/L; (5) Patients are reluctant to cooperate or not completed with researchers syndrome and the integrity of the information about the history of acquisition; (6) With severe drug allergy or blood dialyzer allergic reaction of the patients.

Design outcomes

Primary

MeasureTime frame
Urinary urea concentration;Blood urea concentration;Urinary creatinine;Blood creatinine;Plasma calcium;Plasma phosphorus;Ferritin;Serum cholesterol;Parathyroid hormone;Fibroblast growth factor 23;Plasma albumin;Plasma protein;8-hydroxy-2'-deoxyguanosine;Thioredoxin;Advanced oxidation protein products;High sensitivity C-reactive protein;interleukin-6;Hemoglobin;Red blood cell;Cystatin C;

Countries

China

Contacts

Public ContactJunming Fan
junmingfan@163.com+86 13808285633

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026